Constitutive activation of IRE1 and PERK and their associated downstream pathways has been reported in multiple cancers including triple negative breast cancer, prostate cancer, lung cancer, and, more recently, sarcomas including RMS (RMS) [355,356,357]. This evidence concerns the gene ERN1 and prostate carcinoma.